The investigators aim to ascertain how food reward signals and eating behaviour relates to the gut-brain pathway in weight-losing patients after curative surgery for oesophageal cancer, and how this pathway responds to clinical treatment for this unintentional weight loss. The primary outcomes are the blood oxygen level dependent (BOLD) signal on functional MRI (fMRI), and the breakpoint during the progressive ratio task (PRT - a measure of eating behaviour), how these differ in response to multiple clinical treatment options, as well as how they relate to weight gain while on treatment.
The incidence of cancer of the oesophagus (food pipe) is increasing. Improvements in treatment strategies have resulted in more people who remain free from cancer recurrence in the long term following treatment. Surgery is the cornerstone of treatment for patients with oesophageal cancer, but while surgical removal of the tumour (oesophagectomy) may offer the best chance of cure, these are major operations associated with specific long term complications. Poor appetite, weight loss and nutritional impairment are common problems among patients who attain long-term cancer remission and cure after surgery. A new clinic has been established to treat patients who are in remission but who have lost more than 10% of their body weight secondary to the effects of the surgery and struggling to regain weight. These patients will be treated as per standard of care with medications to aid weight gain. The investigators are interested to conduct research into how the reward value of food changes during the clinical treatment pathway. The hypothesis is that there will be an increased reward response to food after medication use, the magnitude of which will correlate with weight gain. To assess this, patients who are already part of this clinic will be approached to have fMRI that can demonstrate changes in brain reward centres as well as a Progressive Ratio Task, which is a direct measure of appetitive behaviour. Changes in brain reward centre responses and appetitive behaviour will be correlated with changes in weight after pharmacotherapy. This may further inform future clinical protocols to provide improved precision medicine.
Study Type
OBSERVATIONAL
Enrollment
30
Patients undergo clinical treatment as indicated, they are studied before and after.
Conway Institute, UCD
Dublin, Ireland
Change in BOLD signal
Measure of food reward on fMRI
Time frame: Before and after 4 weeks of clinical treatment
Change in breakpoint at PRT
Measure of drive to eat
Time frame: Before and after 4 weeks of clinical treatment
Correlation of weight change during treatment with BOLD signal changes
Relationship of food reward changes to weight gain
Time frame: Before and after 4 weeks of clinical treatment
Correlation of weight change during treatment with PRT breakpoint changes
Relationship of eating behaviour changes to weight gain
Time frame: Before and after 4 weeks of clinical treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.